Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNE Study: Immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations
2021-002789-42Phase 4Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of influenza vaccine in influenza, coronavirus disease 2019 (COVID-19) and pneumococcal disease (3 arms), sponsored by Medical University of Innsbruck. Primary endpoints: Primary immune response endpoints and Association between immunological and laboratory parameters and immune response. Started Jul 2021; status: terminated.
02
Drugs
influenza vaccine
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)pneumococcal disease
Beyond the preview
Go deeper on 2021-002789-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002789-42.